Literature DB >> 25832023

Membrane anchor of cytochrome P450 reductase suppresses the uncoupling of cytochrome P450.

Masayoshi Miyamoto1, Taku Yamashita, Yuki Yasuhara, Akinori Hayasaki, Yukari Hosokawa, Hirofumi Tsujino, Tadayuki Uno.   

Abstract

Cytochrome P450 reductase (CPR) is an important redox partner of microsomal CYPs. CPR is composed of a membrane anchor and a catalytic domain that contains FAD and flavin mononucleotide (FMN) as redox centers and mediates electron transfer to CYP. Although the CPR membrane anchor is believed to be requisite for interaction with CYP, its physiological role is still controversial. To clarify the role of the anchor, we constructed a mutant (Δ60-CPR) in which the N-terminal membrane anchor was truncated, and studied its effect on binding properties, electron transfer to CYP2C19, and drug metabolism. We found that Δ60-CPR could bind to and transfer electrons to CYP2C19 as efficiently as WT-CPR, even in the absence of lipid membrane. In accordance with this, Δ60-CPR could mediate metabolism of amitriptyline (AMT) and imipramine (IMP) in the absence of lipids, although activity was diminished. However, Δ60-CPR failed to metabolize omeprazole (OPZ) and lansoprazole (LPZ). To clarify the reason for this discrepancy in drug metabolism, we investigated the uncoupling reaction of the CYP catalytic cycle. By measuring the amount of H2O2 by-product, we found that shunt pathways were markedly activated in the presence of OPZ/LPZ in the Δ60-CPR mutant. Because H2O2 levels varied among the drugs, we conclude that the proton network in the distal pocket of CYP2C19 is perturbed differently by different drugs, and activated oxygen is degraded to become H2O2. Therefore, we propose a novel role for the membrane anchor as a suppressor of the uncoupling reaction in drug metabolism by CYP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25832023     DOI: 10.1248/cpb.c15-00034

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  6 in total

1.  Structural and Functional Studies of the Membrane-Binding Domain of NADPH-Cytochrome P450 Oxidoreductase.

Authors:  Chuanwu Xia; Anna L Shen; Panida Duangkaew; Rattanawadee Kotewong; Pornpimol Rongnoparut; Jimmy Feix; Jung-Ja P Kim
Journal:  Biochemistry       Date:  2019-05-01       Impact factor: 3.162

2.  Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.

Authors:  Angela W Dymond; Karen So; Paul Martin; Yifan Huang; Paul Severin; David Mathews; Eleanor Lisbon; Gabriella Mariani
Journal:  Eur J Clin Pharmacol       Date:  2016-11-26       Impact factor: 2.953

Review 3.  The catalytic function of cytochrome P450 is entwined with its membrane-bound nature.

Authors:  Carlo Barnaba; Katherine Gentry; Nirupama Sumangala; Ayyalusamy Ramamoorthy
Journal:  F1000Res       Date:  2017-05-09

4.  The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners.

Authors:  Francisco Esteves; Diana Campelo; Bruno Costa Gomes; Philippe Urban; Sophie Bozonnet; Thomas Lautier; José Rueff; Gilles Truan; Michel Kranendonk
Journal:  Front Pharmacol       Date:  2020-03-18       Impact factor: 5.810

5.  Enzyme cascade converting cyclohexanol into ε-caprolactone coupled with NADPH recycling using surface displayed alcohol dehydrogenase and cyclohexanone monooxygenase on E. coli.

Authors:  Haijin Tian; Christoph Furtmann; Florian Lenz; Vishnu Srinivasamurthy; Uwe T Bornscheuer; Joachim Jose
Journal:  Microb Biotechnol       Date:  2022-04-27       Impact factor: 6.575

6.  An integrated screening system for the selection of exemplary substrates for natural and engineered cytochrome P450s.

Authors:  Naoki Kanoh; Ayano Kawamata-Asano; Kana Suzuki; Yusuke Takahashi; Takeshi Miyazawa; Takemichi Nakamura; Takashi Moriya; Hiroyuki Hirano; Hiroyuki Osada; Yoshiharu Iwabuchi; Shunji Takahashi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.